Fulton Financial (NASDAQ:FULT) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.50 by 6 percent. This is a 27.03 percent increase over earnings of $0.37 per share from the
Additional analysis of visual acuity loss, genotypic profiles, and retinal imaging data from a 24-month Phase 2 trial of Tinlarebant in adolescent Stargardt disease patients provides further support for the potential of